TELA Bio, Inc. Cash Flow Statement
TELA|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
TELA Bio, Inc. used $41M in operating cash flow and negative free cash flow of $41M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$46.7M | -$44.3M | -$33.3M | -$28.8M | -$22.4M | -$21.1M | -$21.3M |
| Depreciation & Amortization | $428.0K | $383.0K | $231.0K | $221.0K | $278.0K | $463.0K | $761.0K |
| Operating Cash Flow | -$40.9M | -$40.7M | -$30.4M | -$24.5M | -$25.5M | -$19.9M | -$16.4M |
| Capital Expenditures | $611.0K | $872.0K | $627.0K | $167.0K | $197.0K | $62.0K | $114.0K |
| Free Cash Flow | -$41.5M | -$41.6M | -$31.1M | -$24.6M | -$25.7M | -$20.0M | -$16.5M |
| FCF Margin | -70.9% | -100.5% | -105.4% | -135.2% | -166.5% | -241.6% | -388.3% |